Unique ID issued by UMIN | UMIN000018907 |
---|---|
Receipt number | R000021870 |
Scientific Title | Clinical trial on the Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy for elderly patients with advanced pancreatic cancer |
Date of disclosure of the study information | 2015/09/04 |
Last modified on | 2024/01/28 10:50:02 |
Clinical trial on the Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy for elderly patients with advanced pancreatic cancer
Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy for elderly patients
Clinical trial on the Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy for elderly patients with advanced pancreatic cancer
Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy for elderly patients
Japan |
pancreatic cancer
Hepato-biliary-pancreatic medicine |
Malignancy
NO
This clinical trial to evaluate Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy on elderly patients with advanced pancreatic cancer.
Safety,Efficacy
adverse events, completion rates of two cycles chemotherapy, relative dose intensity, postponed rates of chemotherapy, reduced rates of dose, disease control rate and progression free survival
Observational
75 | years-old | <= |
Not applicable |
Male and Female
patients who had been already obtained informed consent for nab-PTX+GEM combination chemotherapy before registration time; histologically proven unresectable pancreatic adenocarcinoma or adenosquamous carcinoma; age more than 75 years; an expected survival period of more than 3 months; Eastern Cooperative Oncology Group performance status 0-1; measurable lesion by RECIST.(Ver.1.1); no prior chemotherapy and radiotherapy; adequate organ function as evidenced by the following laboratory studies within 7 days prior to enrollment (leukocyte count </=12,000/mm3, neutrophil count >= 1.500/mm3, hemoglobin >= 9.0 g/dl, platelets >= 100,000/mm3, AST/ALT </= ULN x 2.5 U/L, total bilirubin </= ULN x 1.25 mg/dL, creatinine clearance>= 60 ml/min, CRP </=1.5 mg/dL, HbA1c <8.4%,); no abnormal electrocardiogram; patients with agreement of this cohort study.
age less than 75 years; impossible to use both iodine and gadolinium due to being allergic to contrast agent; severe mental disorders; any other cases who are regarded as inadequate for study enrollment by investigators.
25
1st name | Mitsuhiro |
Middle name | |
Last name | Kida |
Kitasato University School of Medicine
Department of Gstroenterology
252-0375
1-1-15 Kitasato Minami Sagamihara Kanagawa 252-0375 Japan
81-42-778-8111
m-kida@kitasato-u.ac.jp
1st name | Kosuke |
Middle name | |
Last name | Okuwaki |
Kitasato University School of Medicine
Department of Gstroenterology
252-0375
1-1-15 Kitasato Minami Sagamihara Kanagawa 252-0375 Japan
81-42-778-8111
kokuwaki@kitasato-u.ac.jp
Kitasato University School of Medicine
None
Self funding
Kitasato University Institutional Review Board
1-1-15 Kitasato Minami Sagamihara Kanagawa 252-0375 Japan
81-42-778-7756
rinri@med.kitasato-u.ac.jp
NO
北里大学病院
2015 | Year | 09 | Month | 04 | Day |
Unpublished
Completed
2015 | Year | 09 | Month | 01 | Day |
2015 | Year | 09 | Month | 01 | Day |
2015 | Year | 09 | Month | 07 | Day |
2018 | Year | 02 | Month | 28 | Day |
This clinical trial to evaluate Feasibility and Efficacy of nab-PTX+GEM combination chemotherapy on elderly patients with advanced pancreatic cancer.
2015 | Year | 09 | Month | 04 | Day |
2024 | Year | 01 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021870